Stay updated on Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial

Sign up to get notified when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.15.0 to v2.15.2 and removed older dates, specifically 2025-04-04 and 2025-04-02, while adding new dates of 2025-04-25 and 2025-04-23.
    Difference
    0.2%
    Check dated 2025-04-30T13:53:12.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The webpage has been updated to include new information about Uveal Melanoma and its treatment, specifically mentioning the EudraCT number for a clinical trial and the collaborators involved. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.
    Difference
    65%
    Check dated 2025-04-16T01:47:46.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The webpage has updated its version from v2.14.3 to v2.14.4 and has added new dates for 2025 while removing older dates from 2024.
    Difference
    0.9%
    Check dated 2025-04-08T20:29:58.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T15:38:10.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.9%
    Check dated 2025-02-24T18:18:28.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    0.9%
    Check dated 2025-02-10T09:18:15.000Z thumbnail image

Stay in the know with updates to Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.